Jack Janetzki
Biographic Data
| ID | 8936227 |
|---|---|
| NAME | Jack Janetzki |
| GIVEN NAMES | Jack |
| FAMILY NAME | Janetzki |
| SIGNATURE | JANETZKI J |
| AFFILIATIONS | University of South Australia |
| ORCID | 0000-0002-4171-3504 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Impact of antiretroviral shortages in HIV therapy and prevention uptake in Australia
Human immunodeficiency virus (HIV) remains a major public health priority in Australia, with treatment and prevention efforts underpinned by access to government-subsidised antiretroviral therapy (ART) through the Pharmaceutical Benefits Scheme (PBS). In 2023-2024, multiple tenofovir with emtricitabine products used for HIV treatment and pre-exposure prophylaxis (PrEP) were subject to national shortages, raising concerns about access and continui…
No prominent works on this page.
Impact of antiretroviral shortages in HIV therapy and prevention uptake in Australia
Human immunodeficiency virus (HIV) remains a major public health priority in Australia, with treatment and prevention efforts underpinned by access to government-subsidised antiretroviral therapy (ART) through the Pharmaceutical Benefits Scheme (PBS). In 2023-2024, multiple tenofovir with emtricitabine products used for HIV treatment and pre-exposure prophylaxis (PrEP) were subject to national shortages, raising concerns about access and continui…
Antiretroviral therapy (1 work) · Economic shortage (1 work) · Emtricitabine (1 work) · HIV/AIDS drug development and treatment (1 work) · HIV/AIDS Research and Interventions (1 work) · Pandemic (1 work) · Pharmaceutical Benefits Scheme (1 work) · Pharmaceutical Economics and Policy (1 work) · Pre-exposure prophylaxis (1 work) · Public health (1 work)